

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

Claims 1-16 (canceled)


Claim 17 (currently amended): A compound of formula 1:



wherein Ar^1 is



wherein R^{12} is selected from the group consisting of



R^{13} represents Cl, Br, $\text{COO}(\text{C}_{1-4})\text{alkyl}$ and
 if R^9 is NO_2 , Cl or Br, then R^{13} may also represent F or CH_3 ;

R^{14} , R^{15} ,

R^{31} , R^{32} ,


R^{33} are each independently selected from the group consisting of H, (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl, (C₃₋₇)cycloalkyl-(C₁₋₃)alkyl, (C₂₋₆)alkenyl, O-(C₁₋₄)alkyl, S-(C₁₋₄)alkyl, halo, CF₃, OCF₃, OH, NO₂, CN, SO₂NH₂, SO₂-(C₁₋₄)alkyl, C(O)OR¹ wherein R^1 is H or (C₁₋₄)alkyl, or NR²R³ wherein R^2 and R^3 each independently is H or (C₁₋₄)alkyl;

R^{30} represents H, Cl, Br, COO(C₁₋₄)alkyl; and

X is S or O;

W is CH₂C(O)NR⁶ wherein R^6 is H or (C₁₋₄)alkyl; and

Ar² is selected from the group consisting of




wherein R^9 is halo or NO₂; and if R^{13} is Cl or Br, then R^9 may also represent (C₁₋₃)alkyl;

R^{10} , R^{11} are independently of each other selected from the group consisting of H, (C₁₋₆)alkyl, (C₃₋₇)Cycloalkyl, (C₃₋₇)Cycloalkyl-(C₁₋₃)alkyl, (C₂₋₆)alkenyl, O(C₁₋₆)alkyl, S(C₁₋₆)alkyl, halo, CF₃, OCF₃, OH, NO₂, CN, -NR^{N1}R^{N2}, -C(O)R²¹, -(C₁₋₃)alkyl-C(O)R²¹, -C(O)OR²², -(C₁₋₃)alkyl-C(O)OR²², -SO₂-(C₁₋₃)alkyl-C(O)OR²², wherein R^{21} is (C₁₋₄)alkyl and R^{22} is H or (C₁₋₄)alkyl; -(C₁₋₃)alkyl-C(O)NH₂, C(O)NH₂, S(O)-(C₁₋₆)alkyl, -SO₂-(C₁₋₆)alkyl, -SO₂-phenyl, -SO₂-NH₂, phenyl, phenylmethyl, 2-, 3- or 4-pyridinyl, 1-pyrrolyl, whereby said phenyl, pyridinyl and pyrrolyl may have one or more substituents selected from the group consisting of halo, NO₂, C₁₋₃-alkyl and CF₃;


or a pharmaceutically acceptable salt thereof.

Claim 18 (previously presented): The compound of formula 1 according to claim 17 wherein Ar¹ is



; and

wherein R^{12} is selected from the group consisting of



wherein R^{13} , R^{14} , R^{15} , R^{30} , R^{31} , R^{32} and R^{33} are as defined in claim 17.

Claim 19 (original): The compound of formula 1 according to claim 18 wherein

R^{13} represents Cl or Br and

if R^9 is NO_2 , Cl or Br, then R^{13} may also represent F or CH_3 ;

R^{14} , R^{15} ,


R^{31} , R^{32} ,

R^{33} are each independently selected from the group consisting of H, (C_{1-6}) alkyl, (C_{3-7}) cycloalkyl, (C_{3-7}) cycloalkyl- (C_{1-3}) alkyl, (C_{2-6}) alkenyl, $O-(C_{1-4})$ alkyl, $S-(C_{1-4})$ alkyl, halo, CF_3 , OCF_3 , OH, NO_2 , CN, SO_2NH_2 , $SO_2-(C_{1-4})$ alkyl, $C(O)OR^1$ wherein R^1 is H or (C_{1-4}) alkyl, or NR^2R^3 wherein R^2 and R^3 each independently is H or (C_{1-4}) alkyl; and R^{30} represents Cl or Br.

Claim 20 (original): The compound of formula 1 according to claim 19 wherein **W** is


$CH_2C(O)NH$.

Claim 21 (original): A compound according to claim 17 wherein



Ar^1 is defined as and


wherein R^{12} is selected from the group consisting of



X is S;


W is $\text{CH}_2\text{C}(\text{O})\text{NR}^6$ wherein R^6 is H or (C_{1-4}) alkyl; and

Ar² is




wherein R^9 is halo or NO_2 ; or

Ar² is



wherein R^9 is halo or NO_2 and R^{10} is halo; or

Ar² is




wherein R^9 is halo or NO_2 , and R^{10} is OMe, halo, OH, NO_2 , phenyl, $\text{C}(\text{O})\text{OH}$ or





C(O)OMe.

Claim 22 (canceled)


Claim 23 (original): A compound of formula 1, according to claim 17, wherein **Ar¹** is:



and wherein **R¹²** selected from the group consisting of:




and



Claim 24 (canceled)

Claim 25 (previously presented): A compound of formula **1**, according to claim 17, wherein

Ar^2 is selected from the group consisting of



wherein R^9 is Cl or NO_2 and


$\text{R}^{10\text{A}}$ is C_{1-4} alkyl;

R^{10} is selected from the group consisting of (C_{1-4}) alkyl, (C_{3-7}) cycloalkyl, (C_{3-7}) cycloalkyl- (C_{1-3}) alkyl, (C_{2-6}) alkenyl, $\text{O}(\text{C}_{1-6})$ alkyl, $\text{S}(\text{C}_{1-6})$ alkyl, halo, CF_3 , OCF_3 , OH , NO_2 , CN , $-\text{NR}^{\text{N1}}\text{R}^{\text{N2}}$, $-\text{C}(\text{O})\text{R}^{21}$, $-(\text{C}_{1-3})$ alkyl- $\text{C}(\text{O})\text{R}^{21}$, $-\text{C}(\text{O})\text{OR}^{22}$, $-(\text{C}_{1-3})$ alkyl- $\text{C}(\text{O})\text{OR}^{22}$, $-\text{SO}_2-(\text{C}_{1-3})$ alkyl- $\text{C}(\text{O})\text{OR}^{22}$, $-(\text{C}_{1-3})$ alkyl- $\text{C}(\text{O})\text{NH}_2$, $\text{C}(\text{O})\text{NH}_2$, $-\text{S}(\text{O})-(\text{C}_{1-6})$ alkyl, $-\text{SO}_2-(\text{C}_{1-6})$ alkyl, $-\text{SO}_2$ -phenyl, $-\text{SO}_2$ - NH_2 , phenyl, phenylmethyl, phenyl- SO_2 -, 2-, 3- or 4-pyridinyl, 1-pyrrolyl, whereby said phenyl, pyridinyl and pyrrolyl may have one or more substituents selected from the group consisting of halo, NO_2 , C_{1-3} -alkyl and CF_3 ;

wherein R^{21} is (C_{1-4}) alkyl and R^{22} is H or (C_{1-4}) alkyl;

wherein R^{N1} , R^{N2} each independently represent H or (C_{1-6}) alkyl, whereby R^{N1} and R^{N2} may be covalently bonded to each other to form together with the N-atom to which they are attached to a 4 to 7-membered heterocycle whereby the $-\text{CH}_2$ -group at the position 4 of a 6 or 7-membered heterocycle may be replaced by $-\text{O}-$, $-\text{S}-$ or $-\text{NR}^{\text{N3}}-$ wherein R^{N3} represents H, $-\text{C}(\text{O})\text{OR}^{22}$, (C_{1-6}) alkyl, (C_{3-7}) cycloalkyl or (C_{3-7}) cycloalkyl- (C_{1-3}) alkyl, wherein R^{22} is H or (C_{1-4}) alkyl.

Claim 26 (original): A compound of formula **1**, according to claim 25, wherein Ar^2 is:



Claim 27 (canceled)

Claim 28 (original): A pharmaceutical composition comprising a compound of formula **1** as defined in claim 17, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable carriers.

Claim 29 (canceled)

Claim 30 (original): A pharmaceutical composition for the treatment of HIV infection, comprising a compound of formula **1** as defined in claim 17, or a pharmaceutically acceptable salt thereof.

Claim 31 (canceled)